Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
paad_cptac_2021
Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)
13 awards paid to create it · 0 awards funded work that used it
1. Awards that paid to create this data (6 of 13)
- Antitumor Assessment · Elisa de Stanchina, FRANCESCA M GANY · FY2025–2026
- Comprehensive Analysis and Multi-Omics Data Integration for Cancer-Related Stud… · Ludmila Danilova · FY2019–2026
- Proteogenomic studies aimed at understanding ovarian tumor responses to agents… · Michael Birrer, AMANDA G PAULOVICH · FY2017–2021
- Proteogenomic Translational Research Center for Clinical Proteomic · BRIAN J DRUKER, Karin D Rodland · FY2017–2021
- MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS · Meenakshi Anurag, STEVEN A CARR · FY2017–2021
- iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC · Bing Zhang · FY2016–2020
The best connected are shown.
2. The dataset
3. Articles that used it
4. Awards those articles were funded by
Why one side of this chain is empty
- This dataset has no accession that articles quote, so no reuse can be traced and nothing it enabled is visible.
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| P30CA008748 P30FY2025–2026$48.4M | Antitumor Assessment | API |
| R50CA243627 R50FY2019–2026$975k | Comprehensive Analysis and Multi-Omics Data Integration for Cancer-Related Studies | API |
| U01CA214114 U01FY2017–2021$8.4M | Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit | API |
| U01CA214116 U01FY2017–2021$6.8M | Proteogenomic Translational Research Center for Clinical Proteomic | API |
| U01CA214125 U01FY2017–2021$7.0M | MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS | API |
| U24CA210954 U24FY2016–2020$4.9M | iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC | API |
| U24CA210955 U24FY2016–2020$5.3M | PNNL Proteome Characterization Center | API |
| U24CA210967 U24FY2016–2020$4.1M | University of Michigan Proteogenomics Data Analysis Center | API |
| U24CA210972 U24FY2016–2020$3.3M | Proteogenomic Data Analysis for Cancer Systems Biology and Clinical Translation | API |
| U24CA210979 U24FY2016–2020$4.4M | Integrated high throughput proteogenomic data analysis center for CPTAC | API |
| U24CA210985 U24FY2016–2020$5.3M | The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic Targets | API |
| U24CA210986 U24FY2016–2020$6.4M | Center of Excellence for High Throughput Proteogenomic Characterization | API |
| U24CA210993 U24FY2016–2020$4.6M | Systems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision Medicine | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.